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Aims To assess the effect of fractional flow reserve (FFR)-guided percutaneous coronary intervention (PCI) with con-
temporary drug-eluting stents on the composite of cardiac death or myocardial infarction (MI) vs. medical therapy
in patients with stable coronary lesions.
...................................................................................................................................................................................................
Methods
and results
We performed a systematic review and meta-analysis of individual patient data (IPD) of the three available randomized
trials of contemporary FFR-guided PCI vs. medical therapy for patients with stable coronary lesions: FAME 2
(NCT01132495), DANAMI-3-PRIMULTI (NCT01960933), and Compare-Acute (NCT01399736). FAME 2 enrolled
patients with stable coronary artery disease (CAD), while the other two focused on non-culprit lesions in stabilized
patients after acute coronary syndrome. A total of 2400 subjects were recruited from 54 sites world-wide with 1056 ran-
domly assigned to FFR-guided PCI and 1344 to medical therapy. The pre-specified primary outcome was a composite of
cardiac death or MI. We included data from extended follow-ups for FAME 2 (up to 5.5 years follow-up) and DANAMI-
3-PRIMULTI (up to 4.7 years follow-up). After a median follow-up of 35 months (interquartile range 12–60 months), a re-
duction in the composite of cardiac death or MI was observed with FFR-guided PCI as compared with medical therapy
(hazard ratio 0.72, 95% confidence interval 0.54–0.96; P= 0.02). The difference between groups was driven by MI.
...................................................................................................................................................................................................
Conclusion In this IPD meta-analysis of the three available randomized controlled trials to date, FFR-guided PCI resulted in a
reduction of the composite of cardiac death or MI compared with medical therapy, which was driven by a
decreased risk of MI.
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Introduction
Controversy exists regarding the role of percutaneous coronary
intervention (PCI) of stable epicardial coronary lesions to reduce
death and myocardial infarction (MI). While American guidelines
state that PCI ‘has not been demonstrated to improve survival, [. . .]
may increase the short-term risk of MI, [. . .] [and] does not lower
the long-term risk of MI’,1 European guidelines admit that they ‘suffer
from limitations inherent [. . .] on what is the real benefit from myo-
cardial revascularization’.2 In these discussions, the presence of re-
versible ischaemia plays a pivotal role. As a result of numerous
mechanistic studies, randomized clinical trials, and observational ser-
ies, fractional flow reserve (FFR) has emerged as the gold standard to
guide revascularization.
At least three randomized trials compared FFR-guided PCI vs.
medical therapy in haemodynamically stable patients with stable cor-
onary lesions (patients with stable coronary disease or haemodynam-
ically stable patients presenting with acute coronary syndrome (ACS)
with clear non-culprit lesions after successful PCI of their culprit le-
sion).3–5 The primary endpoint of such trials is typically a composite
of death, MI, or revascularization. Because of the open label design,
patients who did not receive PCI might be more likely to seek medic-
al care, and physicians aware of treatment assignment might be more
likely to recommend revascularization in patients without previous
PCI, thus introducing a risk of bias for the component of revasculari-
zation.6,7 Even though, some trials only included ischaemia-driven4 or
urgent revascularizations,3 the inclusion of revascularization in pri-
mary composite endpoints continues to be criticized.6,8 The ongoing
International Study of Comparative Health Effectiveness with Medical
and Invasive Approaches (ISCHEMIA; ClinicalTrials.gov number,
NCT01471522) therefore specified the composite of cardiovascular
death or MI as primary endpoint before initiation of the trial but, in
view of limited power to detect a clinically relevant difference, subse-
quently had to fall back to their original intention9 and include resus-
citated cardiac arrest and hospitalization for unstable angina or heart
failure as additional components of the primary endpoint.10 To re-
solve a key uncertainty in clinical practice for a frequently performed,
invasive and expensive procedure, we did a collaborative individual
patient data (IPD) meta-analysis of trials that compared FFR-guided
PCI vs. medical therapy in haemodynamically stable patients with sta-
ble coronary lesions using cardiac death or MI as pre-specified pri-
mary composite endpoint.
Methods
This IPD meta-analysis was performed according to a predefined proto-
col. We searched MEDLINE, Embase, and the Cochrane Library to iden-
tify randomized controlled trials of potential interest without language
restriction using the following algorithm: (‘fractional flow reserve’ or FFR)
AND (‘percutaneous coronary intervention’ or ‘percutaneous coronary
interventions’ or PCI* or stent*) AND (random* or trial* or control*).
The search was initially done on 25 March 2017 and last updated on 8
April 2018. We included randomized controlled trials comparing PCI
guided by FFR using second-generation drug-eluting stents (DES) vs. med-
ical therapy for patients with stable coronary stenoses. Patients with sta-
ble coronary stenoses were defined as patients with stable coronary
disease or haemodynamically stable patients presenting with ACS with
clear non-culprit lesions after successful PCI of their culprit lesion.
Fractional flow reserve-guided PCI was defined as the performance of
PCI based on a positive FFR measurement. We excluded trials where PCI
was performed without the use of second-generation DES as well as trials
on haemodynamically unstable patients. We checked reference lists of
relevant studies and contacted experts in the field to identify additional
trials. Two independent reviewers (F.M.Z. and N.P.J.) identified eligible tri-
als and reached consensus in case of discrepancies. After identification of
eligible trials, we invited the trials’ principal investigators to contribute to
the collaborative analysis, reviewed protocols and publications of each
trial, and specified the data requirements in agreement with the principal
investigators, including most up-to-date follow-up data. Data were
checked for missing values and consistency and queries were resolved
through consultation with trialists.
Three independent reviewers (F.M.Z., N.P.J., and P.J.) assessed trials
using the Cochrane Collaboration’s tool for assessing risk of bias in
randomized trials,11 discrepancies were resolved by consensus (see
Supplementary material online, Appendix). The design of the trials was
reported previously.3–5
All trials randomized haemodynamically stable patients with stable
coronary lesions to FFR-guided PCI or medical therapy (see Figure 1).
FAME 2 randomized patients with stable CAD and at least one FFR-posi-
tive lesion with an FFR <_0.80 in 1:1 ratio to either FFR-guided PCI or
medical therapy; patients in whom all angiographically significant stenoses
were FFR negative did not undergo randomization, received medical
therapy and were included in a registry. In DANAMI-3-PRIMULTI and
Compare-Acute, haemodynamically stabilized subjects initially admitted
with an acute ST-segment elevation myocardial infarction (STEMI) and
angiographically significant coronary non-culprit lesions were randomized
after successful PCI of the culprit lesion to FFR-guided PCI or medical
therapy of non-culprit lesions. Randomization ratios were 1:1 in
DANAMI-3-PRIMULTI and 1:2 in Compare-Acute. Ethics committees at
each participating institution approved the trial protocols and all subjects
signed informed consent before randomization. This report was written
in accordance with Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) recommendations.12
Outcomes and definitions
The pre-specified primary outcome for this meta-analysis of IPD was the
composite of cardiac death or MI. Secondary endpoints include the com-
posite of all-cause death or MI and individual components of these com-
posites, MI, cardiac death, and all-cause death. Independent clinical events
committees adjudicated endpoints in each trial using pre-specified defini-
tions. For the definition of peri-procedural MI, FAME 2 required CK-MB
10-fold above the 99th percentile upper reference limit (URL) or five-
fold above URL with clinical evidence of MI; DANAMI-3-PRIMULTI
required troponin five-fold above URL with clinical evidence of MI; and
Compare-Acute required CK-MB three-fold above URL. For chronic
FFR-guided PCI vs. medical therapy 181
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..total or subtotal occlusions, a default FFR value of 0.50 was assumed in all
trials, consistent with prior studies.3,13
Statistical analysis
Baseline categorical variables are reported as counts and percentages and
continuous variables as means and standard deviations, and compared
using appropriate regression models stratified by trial. The primary ana-
lysis was performed according to the intention-to-treat principle includ-
ing all randomized patients in the group they were allocated to. Individual
patient data were combined in a single data set and analysed using a
mixed-effects Cox regression model with baseline hazards stratified by
trial and a random intercept to account for variation between trials in
baseline risk, and a random slope to account for variation between trials
in treatment effect. Treatment effects are presented as hazard ratios
(HRs) and 95% confidence intervals (CIs). Heterogeneity of the treat-
ment effect between trials was quantified using the variance of the ran-
dom slope s2. Proportional-hazards assumptions were tested after
stratification by trial using Schoenfeld residuals. We performed sensitivity
analyses of the primary outcome using a mixed-effects Poisson regression
model with robust sandwich estimators of standard errors,14 and a
mixed-effects flexible parametric model.15 In addition, we used a compet-
ing risk model to simultaneously analyse the two components of the pri-
mary outcome, and used a conventional two-stage fixed-effect meta-
analysis to combine trial-level HRs. Then, we plotted Kaplan–Meier time-
to-first-event curves, superimposing estimates of the cumulative inci-
dence per group predicted from the mixed-effects flexible parametric
survival model, and used the cumulative incidences and their 95% CIs at
5 years follow-up, as predicted from the mixed-effects flexible parametric
survival model, to derive numbers-needed-to-treat, analogous to calcula-
tions done for individual trials.16 The use of a mixed-effects flexible para-
metric survival model to predict cumulative incidences and derive
numbers-needed-to-treat avoided Simpson’s paradox17 due to the 1:2
randomization in Compare-Acute. All analyses were based on the same
data structure, using time-to-first-event analyses throughout.
Pre-specified subgroup analyses of the primary outcome were per-
formed according to clinical presentation (stable CAD vs. ACS) and FFR
status (patients with at least one stable coronary lesion with a positive
FFR of <_0.80 vs. patients with only lesions with a negative FFR of >0.80).
In DANAMI-3-PRIMULTI, FFR was only measured in the experimental
arm, therefore, the trial had to be excluded from the subgroup analysis
according to FFR status. Subgroup analyses of the primary endpoint speci-
fied post hoc were performed according to age (>60 years or <_60 years),
sex, diabetes status, previous MI, and smoking. We separated within-trial
and across-trial interactions and based tests for subgroup-by-treatment
interactions on within-trial interactions,18 except for the subgroup ana-
lysis by clinical presentation, which was by design based on an across-trial
interaction. Landmark analyses of the primary outcome were performed
according to a pre-specified landmark point at 7 days,3 with HRs calcu-
lated separately for events that occurred up to 7 days after randomization
and events that occurred between 8 days and the end of follow-up.
Landmark analyses were accompanied by a test for interaction between
treatment and time (first 7 days vs. subsequent period). The power of our
meta-analysis to detect a 30% relative risk reduction in the primary com-
posite outcome was calculated as described by Turner et al.19 Between-
trial heterogeneity was considered to be low if the between-trial variance
s2 was 0.04 or less.20 Analyses were conducted using R version 3.4.3 (R
Foundation for Statistical Computing, Vienna, Austria) and Stata Release
14.2 (Stata Corp, College Station, TX, USA).
Results
We identified 1286 reports, of which 345 were duplicates and
removed. After reviewing the remaining 941 unique reports, we
found 16 potentially eligible randomized controlled trials (see
Supplementary material online, Figure S1 in Appendix), of these five tri-
als were excluded as a wrong comparator was used,13,21–24 seven tri-
als were excluded as PCI was not based on a positive FFR
measurement,25–31 and one trial because PCI did not include the use
of second-generation DES.32 Three trials met our inclusion criteria:
the Fractional Flow Reserve vs. Angiography for Multivessel
Evaluation 2 (FAME 2) trial (NCT01132495),3 the Third DANish
Study of Optimal Acute Treatment of Patients With STEMI:
PRImary PCI in MULTIvessel Disease (DANAMI-3-PRIMULTI,
Figure 1 Design of trials included in individual patient data meta-analysis.
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..NCT01960933),4 and the Comparison Between FFR-Guided
Revascularization vs. Conventional Strategy in Acute STEMI Patients
With MVD (Compare-Acute) trial (NCT01399736).5 The principal
investigators of all three eligible trials agreed to provide IPD.
All three trials had adequate generation of allocation sequences
and concealment of allocation using central randomization in two3,4
and sealed opaque sequentially number envelopes in one trial.5 All
trials used independent, blinded event adjudication and analysed all
randomized patients in the groups they were originally allocated to
according to the intention-to-treat principle. By design, blinding of
patients and care provider was not possible in any of the trials. As this
is unlikely to result in relevant bias for the types of outcomes ana-
lysed,33 all trials were classified as having low risk of bias.
A total of 2400 subjects from 54 sites were included in Europe,
North America, and Asia, of whom 1056 were randomly assigned to
FFR-guided PCI and 1344 to medical therapy. Baseline characteristics
are summarized in Supplementary material online, Table S1, discharge
medication in Supplementary material online, Table S2. Patients in the
two groups were well balanced with regard to most of the baseline
demographic, medical history, and discharge medication. Over three
quarters of patients were male in both groups. Approximately 19%
of patients had diabetes, and about 19% a history of MI. Due to the
1:2 randomization in Compare-Acute, the crude percentages of
patients with stable CAD were 42% vs. 33%; after stratification by
trial, the difference between groups was 0.0% (95% CI -0.7 to 0.7%,
P> 0.99). As expected, more subjects were discharged on dual anti-
platelet therapy in the FFR-guided PCI arm than the medical therapy
arm (99% vs. 82%, P< 0.001). The percentage of randomized patients
with FFR-negative lesions only was 0% in FAME-2 and 49% in
Compare-Acute. In DANAMI-3-PRIMULTI, FFR was only measured
in the experimental arm, and 31% of randomized patients in this arm
had FFR-negative lesions only. Baseline characteristics according to
....................................................................................
....................................................................................................................................................................................................................
Table 1 Clinical events: primary and secondary endpoints
Estimated cumulative incidence at 5 years Hazard ratio (95% CI) P-value
FFR-guided PCI Medical therapy
Cardiac death or MIa 10.7% (8.4–13.6%) 16.4% (13.3–20.1%) 0.72 (0.54–0.96) 0.02
Death or MI 13.9% (11.2–17.2%) 19.4% (16.0–23.4%) 0.76 (0.59–0.99) 0.04
MI 8.5% (6.5–11.1%) 13.4% (10.7–16.8%) 0.70 (0.51–0.97) 0.03
Cardiac death 3.2% (2.1–5.1%) 3.0% (1.9–4.8%) 1.04 (0.58–1.78) 0.89
All-cause mortality 7.0% (5.2–9.6%) 6.5% (4.7–8.9%) 1.03 (0.69–1.54) 0.89
aPre-specified primary outcome. FFR-guided PCI (N= 1056) and medical therapy (N= 1344).
CI, confidence interval; FFR, fractional flow reserve; MI, myocardial infarction; PCI, percutaneous coronary intervention.
Figure 2 Primary composite endpoint of cardiac death or myocardial infarction. The cumulative incidence of the primary endpoint of cardiac death
or myocardial infarction was significantly reduced in subjects randomized to fractional flow reserve-guided percutaneous coronary intervention com-
pared with medical therapy alone. Dashed lines are crude time-to-event curves and solid lines are fitted cumulative incidence curves as predicted
from a mixed effects flexible parametric model. Only the fitted curves should be used for inferences about the treatment effect.
FFR-guided PCI vs. medical therapy 183
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..clinical presentation (stable CAD vs. ACS) are presented in
Supplementary material online, Table S3.
Primary and secondary endpoints
Table 1 presents the cumulative incidence estimates at 5 years of
follow-up and HRs of primary and secondary endpoints. The corre-
sponding numbers of events and accumulated observation times are
presented in Supplementary material online, Table S4. Figure 2 shows
the crude and fitted cumulative incidence curves for the primary
composite endpoint of cardiac death or MI. After a median follow-up
of 35 months (interquartile range 12–60 months), a 28% relative re-
duction was observed with FFR-guided PCI as compared with medic-
al therapy (HR 0.72, 95% CI 0.54–0.96; P= 0.02). The estimated
cumulative incidence at 5 years was 10.7% (95% CI 8.4–13.6%) for
FFR-guided PCI group and 16.4% (95% CI 13.3–20.1%) for medical
therapy, which resulted in an estimated number-needed-to-treat to
prevent one event up to 5 years of 18 (95% CI 10–72, see
Supplementary material online, Table S5 in Appendix). The between-
group difference in the primary composite endpoint was driven by a
between-group difference in MI (HR 0.70, 95% CI 0.51–0.97;
P= 0.03), with an estimated number-needed-to-treat to prevent 1
event up to 5 years of 20 (95% CI 11–87). Conversely, there was little
evidence for a difference between groups in cardiac or all-cause
deaths. For the secondary composite endpoint of all-cause death or
MI, there was 23% relative reduction with FFR-guided PCI (HR 0.76,
95% CI 0.59–0.99; P= 0.04).
Figure 3 presents subgroup analyses of the primary endpoint. We
found little evidence for HRs differing across type of initial presenta-
tion (P for interaction = 0.87), but a statistical trend towards an inter-
action between treatment and FFR (P for interaction = 0.06), with a
particularly pronounced benefit of FFR-guided PCI in patients who
had at least one lesion with an FFR of 0.80 or less (HR 0.62, 95% CI
0.43–0.89; P= 0.01).
Figure 4 and Supplementary material online, Figure S2 in Appendix
present landmark analyses. For the primary composite endpoint of
cardiac death or MI we found a strongly positive interaction between
treatment and time (P for interaction = 0.003), with a non-significant
risk increase with FFR-guided PCI up to 7 days (HR 1.94, 95% CI
0.85–4.42; P= 0.12), but a statistically significant risk reduction with
FFR-guided PCI 8 days or more after randomization (HR 0.62, 95%
CI 0.46–0.85; P= 0.003). The interaction was entirely driven by MI (P
for interaction 0.0015), with a statistical trend towards an increase in
events in the FFR-guided PCI arm up to 7 days (HR 2.51 95% CI 0.96–
6.57; P= 0.06), but a statistically significant reduction of events 8 days
or more after randomization with FFR-guided PCI (HR 0.59, 95% CI
0.42–0.83; P= 0.002). There was no evidence for an interaction be-
tween treatment and time for cardiac death (P for interaction = 0.83).
Figure 3 Subgroup analyses of primary composite endpoint of cardiac death or myocardial infarction. Pre-specified subgroup analyses of the pri-
mary outcome are shown according to clinical presentation (stable coronary artery disease vs. acute coronary syndrome) and fractional flow reserve
status (patients with at least one stable coronary lesion with a positive fractional flow reserve of <_0.80 vs. patients with only lesions with a negative
fractional flow reserve of >0.80). The Post hoc subgroup analyses of the primary endpoint specified are shown according to age (>60 years or <_60
years), sex, diabetes status, previous myocardial infarction, and smoking. CAD, coronary artery disease; FFR, fractional flow reserve; HR, hazard ratio;
MT, medical therapy; PCI, percutaneous coronary intervention. P-values for interaction are for within-trial interaction unless indicated otherwise.
*P-value for interaction is for across-trial interaction.
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Results of sensitivity analyses were much the same as those of
primary analyses (Supplementary material online, Table S6 in Appendix),
as were results of competing risk model (Supplementary material on-
line, Table S7 in Appendix) and two-stage meta-analysis (Supplementary
material online, Figure S3). Tests of proportional hazards assumption
were negative for the primary composite outcome (P= 0.15) and all
secondary outcomes (P>_ 0.09). Heterogeneity in treatment effects be-
tween trials was low for all outcomes (s2 < 0.001). The power of the
meta-analysis to detect a 30% relative reduction was 68%. We identi-
fied no issues regarding the integrity of the IPD.
Discussion
Our IPD meta-analysis of three randomized trials showed a statistic-
ally significant reduction in the pre-specified composite endpoint of
cardiac death or MI favouring FFR-guided PCI over medical therapy.
Fractional flow reserve-guided PCI also reduced the composite of all-
cause death or MI. Differences were driven by a reduction in MI, with
little evidence for a reduction in cardiac or all-cause death. The rela-
tive reduction of PCI of about 28% corresponds to an estimated 5.7%
absolute risk reduction at 5 years and a number-needed-to-treat of
18, which is clinically relevant and in keeping with many other stand-
ard treatments.
Two factors are likely to explain negative results for analysed out-
comes seen in individual trials. First, each trial by itself was underpow-
ered for a composite of cardiac death or MI. Because all trials were
powered for a primary composite endpoint that included various def-
initions of revascularization as one of its components, it cannot be
expected that a statistically significant reduction in cardiac death or
MI would be found in any single trial. Each component trial in our ana-
lysis had recruited less than 1000 patients and ascertained its primary
endpoint between 1 year and 2 years of follow-up, and none of the
trials had more than 25% power to detect, for example, a 30% rela-
tive risk reduction in the composite of cardiac death or MI. Our ana-
lysis included 2400 patients at a median of almost 3 years of follow-
up, accordingly, its power to detect a 30% relative risk reduction20 is
above 65%. While this is still below the optimum of 80–90%, it is con-
siderably above the average observed in meta-analyses of cardiovas-
cular trials.20 Second, prior randomized trials, such as COURAGE,27
used PCI with bare-metal or early generation DES guided by angiog-
raphy, which was found inferior to modern PCI with modern gener-
ation DES34 and FFR-guidance.14
This meta-analysis included stable lesions from subjects presenting
with both stable coronary disease and stabilized acute STEMI. While
the clinical presentation differs, both physiologic and statistical argu-
ments plus recent guideline recommendations justify combining these
studies. First, in contrast to culprit lesions,35 FFR-values in non-culprit
vessels usually do not change much between assessments made dur-
ing the acute phase of a STEMI and assessments weeks or months
later during the stable phase of coronary disease.36–39 Therefore, the
vast majority of lesions which were classified as FFR-positive during
the acute phase will also be classified as FFR-positive during the subse-
quent stable phase of coronary disease. Second, STEMI patients were
only included in the trials after successful opening of the culprit vessel,
when they were haemodynamically stable. Third, the heterogeneity in
treatment effects between trials was low and there was no evidence
for an interaction between clinical presentation and treatment effect,
with near identical relative reductions of the primary endpoint of 30%
observed in patients with stable CAD and 28% in patients who initially
presented with stabilized ACS. Finally, the recent European guidelines
on myocardial revascularization40 state that ‘after PCI of the culprit le-
sion in [an acute coronary syndrome], the choice of further revascula-
rization modality should follow the criteria applied to patients with
[stable coronary artery disease]’.
Lesion selection is critically important when assessing the benefit
of FFR-guided PCI over medical therapy. If patients who only have
FFR-negative lesions are randomized and included in the analysis—as
in DANAMI-3-PRIMULTI4 and Compare-Acute5 based on angio-
graphic inclusion criteria—then a substantial proportion of patients
receives the same, typically conservative treatment regardless of ran-
domization and the effect of FFR-guided PCI will be diluted in an
Figure 4 Landmark analyses of primary composite endpoint and its components. The hazard ratios of the primary composite outcome of cardiac
death or myocardial infarction and of components of the primary composite outcome shown according to the time from randomization (7 days or
less vs. 8 days or more). The solid boxes represent hazard ratios for 7 days or less after randomization, the open boxes represent hazard ratios for 8
days or more from randomization. Arrows indicate that the ends of the confidence interval are either less than 0.4 or more than 5. FFR, fractional
flow reserve; HR, hazard ratio; PCI, percutaneous coronary intervention.
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intention-to-treat analysis. In our meta-analysis, an estimated 26% of
randomized patients had only FFR-negative lesions. Nevertheless, a
statistically significant 28% reduction in the composite of cardiac
death or MI was found. In a subgroup analysis by FFR, a more pro-
nounced, 38% reduction was indeed found in patients with at least
one FFR-positive lesion. While we acknowledge that the test for
interaction between FFR status and treatment effect showed only a
statistical trend (P= 0.06) and DANAMI-3-PRIMULTI could not be
included in this analysis as FFR status was unknown for the control
group of this trial,4 we consider it likely that the 38% relative reduc-
tion of the primary endpoint in the FFR positive subgroup of patients
is a true reflection of the benefit of modern FFR-guided PCI in
patients with haemodynamically significant stable coronary lesions.
Of note, the recent ORBITA trial comparing PCI with a sham inter-
vention included 29% of patients with FFR negative lesions only.26 In
contrast to the trials included in our analysis, these patients typically
received PCI if they were allocated to the experimental arm, even
though PCI is unlikely to improve symptoms or prognosis in patients
without haemodynamically significant lesions.7,14,28
Several ongoing trials have the potential to corroborate or re-
fute our findings. In the ISCHEMIA trial, an invasive strategy will be
compared with initial medical therapy in patients with stable CAD
and moderate ischaemia (NCT01471522), using a primary com-
posite endpoint of cardiovascular death, MI, resuscitated cardiac
arrest, or hospitalization for unstable angina or heart failure.
ISCHEMIA recently completed recruitment of almost 5200 sub-
jects. Despite its complex design, it may be possible to isolate a
subset of patients with FFR-positive lesions randomized to revas-
cularization or medical therapy. In the FULL REVASC trial, FFR-
guided PCI will be compared with initial medical therapy of non-
culprit lesions in STEMI patients (NCT02862119). The trial will
randomize about 4000 patients and use a primary composite end-
point of all-cause mortality or MI. Notably, it will include both
patients with FFR-positive and FFR-negative lesions, which will di-
lute the benefit of the experimental strategy as seen in Compare-
Acute and DANAMI-PRIMULTI.4,5
Our analysis should be interpreted in view of several limitations.
First, patients and their physicians were not blinded to the allocated
strategy. In addition, there was variation between trials in the disclos-
ure of FFR values to patients and physicians. However, knowledge of
the allocated strategy and of FFR values is unlikely to bias estimates
of our primary composite outcome of cardiac death or MI in favour of
the experimental strategy.12 If anything, knowledge of the treatment
strategy and FFR values might have rendered patients in control groups
more likely to cross over to an invasive strategy. Therefore, an inten-
tion- to-treat analysis is likely to underestimate the potential benefit of
FFR-guided PCI as compared with medical therapy with regard to our
primary outcome of cardiac death or MI.7 The higher use of dual anti-
platelet therapy in the FFR-guided PCI group could provide an alterna-
tive or complementary explanation for the observed benefit instead of
FFR-guided PCI itself, especially since many subsequent events occur in
non-target vessels.39 Nevertheless the curves continue to diverge be-
yond 1 year follow-up, where the majority of patients in both groups is
assumed to receive single antiplatelet therapy.
Although FFR provides a lesion- or vessel-specific diagnostic tool,
subsequent clinical events were not adjudicated with this level of spe-
cificity. Non-target vessel events (e.g. a subsequent MI in a vessel not
interrogated with FFR) have little or no mechanistic link to FFR in the
target vessel. The distinction between cardiac and non-cardiac death
can be complex and subjective. However, all trials had a blind, inde-
pendent adjudication of events, including death and MI. Finally, we did
not distinguish between peri-procedural and spontaneous MI. In add-
ition, information on infarction size or presence of Q waves was not
obtained. However, our landmark analysis confirmed an early in-
crease in MI with early FFR-guided PCI within 7 days, followed by a
pronounced benefit, with a 41% relative reduction of MI beyond
7 days (P= 0.003), as also seen in FAME 2 alone.3
Conclusion
In this IPD meta-analysis of the three available randomized controlled
trials to date, FFR-guided PCI resulted in a reduction of the compos-
ite of cardiac death or MI compared with medical therapy, which was
driven by a decreased risk of MI.
Supplementary material
Supplementary material is available at European Heart Journal online.
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